<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02059460</url>
  </required_header>
  <id_info>
    <org_study_id>Terli-NGAL-111</org_study_id>
    <nct_id>NCT02059460</nct_id>
  </id_info>
  <brief_title>Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney</brief_title>
  <acronym>Terli-NGAL</acronym>
  <official_title>Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Liver Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Mohamed Helmi Ibrahim Afifi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Khaled Ahmed Yassen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Khalid Mousa Abouelenain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Mohamed Abdelrauf kandil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Ayman Alsebaey Qotb Alghoraieb.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Liver Institute, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the impact of intra and post-operative Terlipressin infusion on the occurrence of&#xD;
      acute kidney injury after LDLT To investigate perioperative Neutrophil Gelatinase Associated&#xD;
      Lipocalin (NGAL) changes and study the effect of Terlipressin on NGAL blood levels&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted after approval of the local ethics and research committee of&#xD;
      anesthesia, ICU and pain management of both Faculty of Medicine and Liver Institute, Menoufia&#xD;
      University, Egypt. This study will be conducted in Anesthesia Department, National Liver&#xD;
      Institute hospital on patients undergoing liver transplantation. They will be simply&#xD;
      randomized with closed envelopes into two groups. Terlipressin group and Control group. A&#xD;
      written informed consent will be taken from every patient.&#xD;
&#xD;
      Inclusion criteria: Adult living donor liver transplant recipients with no preoperative renal&#xD;
      dysfunction Exclusion criteria: patients with renal insufficiency defined as serum creatinine&#xD;
      &gt; 2 mg/dl and GFR &lt;60 ml/min by isotope scanning of the kidney.&#xD;
&#xD;
      Anesthetic Technique:&#xD;
&#xD;
      All patients will be monitored by electrocardiography, noninvasive and invasive arterial&#xD;
      blood pressure, pulse oximetry, capnography, fraction inspired oxygen concentration (FiO2).&#xD;
      After preoxygenation, general anesthesia will be induced with Propofol 2 mg/kg IV, Fentanyl 2&#xD;
      µg/kg IV and Rocronium 0.9 mg/kg IV followed by endotracheal intubation and maintenance with&#xD;
      a mixture of air, oxygen 50% with Desﬂurane. Mechanical ventilation will be adjusted to&#xD;
      maintain end-tidal CO2 between 35-40 mmHg. Central venous line will be inserted for&#xD;
      monitoring of central venous pressure (CVP) with ultrasonography guidance.&#xD;
&#xD;
      The esophageal Doppler probe will then be inserted orally and positioned approximately 35-40&#xD;
      cm from the teeth (CardioQTM®, Deltex Medical, Chichester, UK). Normothermia (core&#xD;
      temperature &gt; 36°C) will be maintained intraoperatively using forced warming air blanket&#xD;
      (Bair Hugger®; Arizant, UK).&#xD;
&#xD;
      After induction of anesthesia patients will be randomly divided into two groups Terlipressin&#xD;
      group, Terlipressin (Glypressin®, Rentschler biotechnology Gmbh, Erwin, Germany) will be&#xD;
      started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively. In the&#xD;
      control group, continuous placebo infusion will be started. The Anesthesia team will be kept&#xD;
      blind to the contents of the infusion.&#xD;
&#xD;
      Rotetional thromboelastometry [ROTEM] will guide intraoperative blood transfusion protocol as&#xD;
      prescribed by the study of Gorlinger K will be followed in both groups. (13) Platelets will&#xD;
      be substituted when maximum clot firmness of (MCF EXTEM) &lt;45mm and maximum clot firmness of&#xD;
      FIBTEM (MCF FIBTEM) &gt;8mm.&#xD;
&#xD;
      Fresh frozen plasma will be administerd when clot formation time representing extrinsic&#xD;
      coagulation pathway (CFT EXTEM) was &gt;240sec. Hematocrite will be kept more than or equal to&#xD;
      25 with packed red blood cells units.&#xD;
&#xD;
      All patients will receive intraoperative methylprednisolone (10 mg/kg). Hemodynamics will be&#xD;
      maintained, keeping mean blood pressure above 60 mmHg by fluids and vasoactive drugs.&#xD;
&#xD;
      After surgery, all patients will be transferred to the intensive care unit for controlled&#xD;
      mechanical ventilation. The patients will be extubated when hemodynamics are stable, liver&#xD;
      graft functions satisfactory, sufficient spontaneous breathing, and core temperature &gt;36°C.&#xD;
&#xD;
      Measured Parameters:&#xD;
&#xD;
      -Evaluation of renal function and injury:&#xD;
&#xD;
        -  Serum Cr levels and BUN will be determined preoperatively and then daily up to 5 days&#xD;
           after surgery.&#xD;
&#xD;
        -  The glomerular ﬁltration rate (GFR) or the nearest approximation of GFR will be&#xD;
           calculated from the equation of modiﬁcation of Diet in Renal Disease Study on the basis&#xD;
           of obtained serum Cr levels and patient demographics.&#xD;
&#xD;
        -  Urine output&#xD;
&#xD;
        -  Determination of NGAL Blood samples for the determination of NGAL will be drawn at 3&#xD;
           different time points: immediately after the induction of anesthesia, 2 hours after&#xD;
           reperfusion, and 24 hours after reperfusion.&#xD;
&#xD;
      Blood samples will be drawn at the predetermined time points and processed within 2 hours&#xD;
      after collection. Serum will be collected and subsequently frozen at -80°Celsius until&#xD;
      further analysis -Hemodynamic parameters:&#xD;
&#xD;
      • Heart rate, mean arterial blood pressure [MABP], and CVP, cardiac output (COP), stroke&#xD;
      volume (SV), corrected flow time (FTc), systemic vascular resistance (SVR) will be recorded&#xD;
      after induction of anesthesia, then every hour during the operation.&#xD;
&#xD;
      Other parameters:&#xD;
&#xD;
        -  Anhepatic phase time, warm and cold ischemia time.&#xD;
&#xD;
        -  Graft weight , recipient graft body weight ratio.&#xD;
&#xD;
        -  Fluid, blood product transfusion.&#xD;
&#xD;
        -  Blood glucose level, postoperative complication.&#xD;
&#xD;
        -  ICU stay, length of hospital stay.&#xD;
&#xD;
        -  30 days mortality The need for postoperative renal replacement therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of acute kidney injury</measure>
    <time_frame>5 days postoperatuvely</time_frame>
    <description>it is elevation of serum creatinine &gt;1.5 mg/dL</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Liver Transplantation</condition>
  <condition>Terlipressin</condition>
  <condition>NGAL</condition>
  <arm_group>
    <arm_group_label>Terlipressin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terlipressin group, Terlipressin (Glypressin®, Rentschler biotechnology Gmbh, Erwin, Germany) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively</description>
    <arm_group_label>Terlipressin group</arm_group_label>
    <other_name>Glypressin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult living donor liver transplant recipients with no preoperative renal dysfunction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with renal insufficiency defined as serum creatinine &gt; 2 mg/dl and GFR &lt;60&#xD;
             ml/min by isotope scanning of the kidney.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanaa S Rashed, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Liver Institute, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Liver Institute</name>
      <address>
        <city>Shebeen Alkom</city>
        <state>Menoufiya</state>
        <zip>32511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://www.renal.org/clinical/guidelinessection/AcuteKidneyInjury.aspx</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1002/lt.21682/full</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, Angeli P, Moreau R, Davenport A, Jalan R, Ronco C, Genyk Y, Arroyo V. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011 May;60(5):702-9. doi: 10.1136/gut.2010.236133. Epub 2011 Feb 15.</citation>
    <PMID>21325171</PMID>
  </reference>
  <reference>
    <citation>Hong SH, Lee JM, Choi JH, Chung HS, Park JH, Park CS. Perioperative assessment of terlipressin infusion during living donor liver transplantation. J Int Med Res. 2012;40(1):225-36.</citation>
    <PMID>22429362</PMID>
  </reference>
  <reference>
    <citation>Saner FH, Canbay A, Gerken G, Broelsch CE. Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome. Expert Rev Gastroenterol Hepatol. 2007 Dec;1(2):207-17. doi: 10.1586/17474124.1.2.207. Review.</citation>
    <PMID>19072411</PMID>
  </reference>
  <reference>
    <citation>Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003 Oct;14(10):2534-43.</citation>
    <PMID>14514731</PMID>
  </reference>
  <reference>
    <citation>Rostami Z, Nikpoor M, Einollahi B. Urinary Neutrophil Gelatinase Associated Lipocalin (NGAL) for Early Diagnosis of Acute Kidney Injury in Renal Transplant Recipients. Nephrourol Mon. 2013 Spring;5(2):745-52. doi: 10.5812/numonthly.9385. Epub 2013 Mar 30.</citation>
    <PMID>23841038</PMID>
  </reference>
  <reference>
    <citation>Afonso RC, Hidalgo R, Zurstrassen MP, Fonseca LE, Pandullo FL, Rezende MB, Meira-Filho SP, Ferraz-Neto BH. Impact of renal failure on liver transplantation survival. Transplant Proc. 2008 Apr;40(3):808-10. doi: 10.1016/j.transproceed.2008.02.062.</citation>
    <PMID>18455024</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>November 10, 2013</study_first_submitted>
  <study_first_submitted_qc>February 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2014</study_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Liver Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Hanaa Rashed</investigator_full_name>
    <investigator_title>Assistant lecturer of Anesthesia and Intensive Care</investigator_title>
  </responsible_party>
  <keyword>Terlipressin</keyword>
  <keyword>Acute kidney injury</keyword>
  <keyword>Liver transplantation</keyword>
  <keyword>NGAL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 4, 2017</submitted>
    <returned>February 23, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

